Cargando…
A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD
BACKGROUND: Administering maintenance COPD therapy with a combination of multiple inhalers may increase inhaler errors. This study evaluated the potential benefits of using a single Ellipta dry powder inhaler (DPI) compared with two combinations of DPIs commonly used to deliver triple maintenance th...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110160/ https://www.ncbi.nlm.nih.gov/pubmed/30174421 http://dx.doi.org/10.2147/COPD.S169060 |
_version_ | 1783350425469059072 |
---|---|
author | van der Palen, Job Moeskops-van Beurden, Wendy Dawson, Carolyn M James, Wai-Yee Preece, Andrew Midwinter, Dawn Barnes, Neil Sharma, Raj |
author_facet | van der Palen, Job Moeskops-van Beurden, Wendy Dawson, Carolyn M James, Wai-Yee Preece, Andrew Midwinter, Dawn Barnes, Neil Sharma, Raj |
author_sort | van der Palen, Job |
collection | PubMed |
description | BACKGROUND: Administering maintenance COPD therapy with a combination of multiple inhalers may increase inhaler errors. This study evaluated the potential benefits of using a single Ellipta dry powder inhaler (DPI) compared with two combinations of DPIs commonly used to deliver triple maintenance therapy. METHODS: Patients receiving inhaled COPD medication were enrolled in this multicenter, randomized, open-label, placebo-device, crossover study with a 2×2 complete block design (NCT0298218), which comprised two substudies: Ellipta vs Diskus + HandiHaler (substudy 1) or Turbuhaler + HandiHaler (substudy 2). Patients demonstrated inhaler use after reading the relevant patient information leaflet (PIL). A trained investigator assessed user errors (critical errors [errors likely to result in no or significantly reduced medication being inhaled] and overall errors). The primary endpoint was the proportion of patients making ≥1 critical error after reading the PIL. The secondary endpoints included error rates during ≤2 reassessments following investigator instruction (if required), instruction time, and patient preference. RESULTS: After reading the PIL, significantly fewer patients made critical errors with Ellipta compared with Diskus + HandiHaler (9% [7/80] vs 75% [60/80], respectively; P<0.001) or Turbuhaler + HandiHaler (9% [7/79] vs 73% [58/79], respectively; P<0.001). The number of patients making overall errors was also lower with Ellipta vs tested inhaler combinations (P<0.001 for each substudy). The median instruction time needed for error-free use was shorter with Ellipta in substudies 1 and 2 (2.7 and 2.6 minutes, respectively) vs either combination (10.6 [Diskus + HandiHaler] and 11.3 minutes [Turbuhaler + HandiHaler], respectively). Significantly more patients preferred Ellipta over Diskus + HandiHaler or Turbuhaler + HandiHaler overall for taking their COPD medication (81% vs 9% and 84% vs 4%, respectively) and per the number of steps for taking their COPD medication (89% vs 8% and 91% vs 5%, respectively). CONCLUSION: Fewer patients with COPD made critical errors with the single DPI, and patients required less instruction time, compared with each dual DPI combination. |
format | Online Article Text |
id | pubmed-6110160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61101602018-08-31 A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD van der Palen, Job Moeskops-van Beurden, Wendy Dawson, Carolyn M James, Wai-Yee Preece, Andrew Midwinter, Dawn Barnes, Neil Sharma, Raj Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Administering maintenance COPD therapy with a combination of multiple inhalers may increase inhaler errors. This study evaluated the potential benefits of using a single Ellipta dry powder inhaler (DPI) compared with two combinations of DPIs commonly used to deliver triple maintenance therapy. METHODS: Patients receiving inhaled COPD medication were enrolled in this multicenter, randomized, open-label, placebo-device, crossover study with a 2×2 complete block design (NCT0298218), which comprised two substudies: Ellipta vs Diskus + HandiHaler (substudy 1) or Turbuhaler + HandiHaler (substudy 2). Patients demonstrated inhaler use after reading the relevant patient information leaflet (PIL). A trained investigator assessed user errors (critical errors [errors likely to result in no or significantly reduced medication being inhaled] and overall errors). The primary endpoint was the proportion of patients making ≥1 critical error after reading the PIL. The secondary endpoints included error rates during ≤2 reassessments following investigator instruction (if required), instruction time, and patient preference. RESULTS: After reading the PIL, significantly fewer patients made critical errors with Ellipta compared with Diskus + HandiHaler (9% [7/80] vs 75% [60/80], respectively; P<0.001) or Turbuhaler + HandiHaler (9% [7/79] vs 73% [58/79], respectively; P<0.001). The number of patients making overall errors was also lower with Ellipta vs tested inhaler combinations (P<0.001 for each substudy). The median instruction time needed for error-free use was shorter with Ellipta in substudies 1 and 2 (2.7 and 2.6 minutes, respectively) vs either combination (10.6 [Diskus + HandiHaler] and 11.3 minutes [Turbuhaler + HandiHaler], respectively). Significantly more patients preferred Ellipta over Diskus + HandiHaler or Turbuhaler + HandiHaler overall for taking their COPD medication (81% vs 9% and 84% vs 4%, respectively) and per the number of steps for taking their COPD medication (89% vs 8% and 91% vs 5%, respectively). CONCLUSION: Fewer patients with COPD made critical errors with the single DPI, and patients required less instruction time, compared with each dual DPI combination. Dove Medical Press 2018-08-21 /pmc/articles/PMC6110160/ /pubmed/30174421 http://dx.doi.org/10.2147/COPD.S169060 Text en © 2018 van der Palen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research van der Palen, Job Moeskops-van Beurden, Wendy Dawson, Carolyn M James, Wai-Yee Preece, Andrew Midwinter, Dawn Barnes, Neil Sharma, Raj A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD |
title | A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD |
title_full | A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD |
title_fullStr | A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD |
title_full_unstemmed | A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD |
title_short | A randomized, open-label, single-visit, crossover study simulating triple-drug delivery with Ellipta compared with dual inhaler combinations in patients with COPD |
title_sort | randomized, open-label, single-visit, crossover study simulating triple-drug delivery with ellipta compared with dual inhaler combinations in patients with copd |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110160/ https://www.ncbi.nlm.nih.gov/pubmed/30174421 http://dx.doi.org/10.2147/COPD.S169060 |
work_keys_str_mv | AT vanderpalenjob arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT moeskopsvanbeurdenwendy arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT dawsoncarolynm arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT jameswaiyee arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT preeceandrew arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT midwinterdawn arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT barnesneil arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT sharmaraj arandomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT vanderpalenjob randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT moeskopsvanbeurdenwendy randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT dawsoncarolynm randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT jameswaiyee randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT preeceandrew randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT midwinterdawn randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT barnesneil randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd AT sharmaraj randomizedopenlabelsinglevisitcrossoverstudysimulatingtripledrugdeliverywithelliptacomparedwithdualinhalercombinationsinpatientswithcopd |